Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-227 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1: (Treatment A + Treatment B + Treatment C) | EXPERIMENTAL | TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing. |
| Sequence 2: (Treatment B + Treatment C + Treatment A) | EXPERIMENTAL | TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A . There will be a washout period of at least 4 days between each dosing. |
| Sequence 3: (Treatment C + Treatment A + Treatment B) | EXPERIMENTAL | TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing. |
| Sequence 4: (Treatment A + Treatment C + Treatment B) | EXPERIMENTAL | TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing. |
| Sequence 5: (Treatment B + Treatment A + Treatment C) | EXPERIMENTAL | TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing. |
| Sequence 6: (Treatment C + Treatment B + Treatment A) | EXPERIMENTAL | TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A. There will be a washout period of at least 4 days between each dosing. |
| Name | Type | Description |
|---|---|---|
| TAK-227 | DRUG | TAK-227 capsules. |
Inclusion Criteria Participants must fulfill the following inclusion criteria to be eligible for participation in the study: * Body mass index (BMI) greater than or equal to (\>=) 18 and less than or equal to (\<=) 32.0 kilogram per square meter (kg/m\^2) at screening visit. * Continuous non-smoke...
TAK-227 is an investigational small molecule being developed by Takeda Pharmaceutical Company Limited. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other. TAK-227 is not approved and remains in clinical investigation.
TAK-227 is being studied for use in healthy volunteers. The completed Phase 1 trial, NCT05818956, enrolled healthy adults to evaluate the drug. As an investigational agent, its potential therapeutic use has not been established, and it is not approved for any condition.
TAK-227 is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical trial for this investigational small molecule. The drug is currently in Phase 1 development.
TAK-227 is in Phase 1 clinical development. A single Phase 1 trial, NCT05818956, has been completed. The drug is investigational and has not been approved by regulatory authorities. It remains in early-stage clinical testing.
TAK-227 has one completed Phase 1 clinical trial, NCT05818956, titled "A Study of TAK-227 in Healthy Adults." This trial enrolled 24 participants in the United States, with ages 18 years and older. The trial was controlled and randomized, though not double-blinded.
TAK-227 is the only name provided for this investigational drug. No alternative names have been identified for this small molecule being developed by Takeda. It is currently in Phase 1 clinical development for healthy volunteers.